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Abstract
Oropouche (ORO) virus, a member of the Simbu serogroup, is one of the few human pathogens in the Orthobunyavirus
genus in the family Bunyaviridae. Genetic analyses of ORO-like strains from Iquitos, Peru, identified a novel reassortant
containing the S and L segments of ORO virus and the M segment of a novel Simbu serogroup virus. This new pathogen,
which we named Iquitos (IQT) virus, was first isolated during 1999 from a febrile patient in Iquitos, an Amazonian city in
Peru. Subsequently, the virus was identified as the cause of outbreaks of ‘‘Oropouche fever’’ during 2005 and 2006 in
Iquitos. In addition to the identification of 17 isolates of IQT virus between 1999 and 2006, surveys for neutralizing antibody
among Iquitos residents revealed prevalence rates of 14.9% for ORO virus and 15.4% for IQT virus. Limited studies indicate
that prior infection with ORO virus does not seem to protect against disease caused with the IQT virus infection.
Identification of a new Orthobunyavirus human pathogen in the Amazon region of Peru highlights the need for
strengthening surveillance activities and laboratory capabilities, and investigating the emergence of new pathogens in
tropical regions of South America.
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Introduction
Viruses in the family Bunyaviridae are classified into five genera:
Orthobunyavirus, Hantavirus, Nairovirus, Phlebovirus and Tospoviruses.T h e
orthobunyaviruses are enveloped, negative sense RNA viruses whose
genome comprises three segments: small (S), medium (M) and large
(L). The S segment encodes for the nucleocapsid and a nonstructural
protein, NSs. The M segment encodes for the glycoproteins Gn and
Gc, whereas the L segment encodes the viral polymerase. Some
members of the Orthobunyavirus genus are known to cause clinical
disease in humans, including Oropouche (ORO) virus, a member of
the Simbu serogroup, which causes a febrile disease often associated
with headache, dizziness, weakness, myalgias and arthralgias [1].
Bunyamwera virus, which is considered the prototype member of the
family, causes a febrile illness with headache, arthralgias, rash and
infrequent central nervous system involvement [2]. Hemorrhagic
manifestations associated with some orthobunyavirus infections have
also been reported recently [3,4].
Genetic reassortment among members of the same serogroup
within the Orthobunyavirus genus occurs in nature and has led to the
emergence of new viruses, occasionally with increased pathoge-
nicity. This appears to be the case with Ngari virus, which has
been associated with hemorrhagic fever in Kenya and Somalia
[3,5]. This virus is comprised of the S and L segments of
Bunyamwera virus and the M segment of Batai virus [4]. On the
basis of genetic and antigenic analyses, we previously reported that
Jatobal virus (JAT), a member of the Simbu serogroup, is a
reassortant virus that contains the S segment of ORO virus and
the M and L segments of a still unrecognized Simbu serogroup
virus [6].
Within the Orthobunyavirus genus, 18 serogroups have been
recognized on the basis of the results of cross-hemagglutination
inhibition (HAI) and antibody neutralization relationships [7]. The
Simbu serogroup contains at least 25 members, and recent
phylogenetic analyses demonstrated that the genetic relationships
amongst these viruses are consistent with the results of serological
relationships [7,8]. ORO virus was originally isolated in 1955 from
blood of a febrile forest worker who lived in Vega de Oropouche,
Trinidad [9]. Outbreaks involving thousands of human cases
continue to be reported in Brazil [10,11,12,13], and circulation of
the virus has been reported in Panama, Peru, and Trinidad
[14,15,16,17]. Based on the S segment, three genotypes of ORO
virus were distinguished phylogenetically: genotype I includes the
isolates from Brazil and Trinidad, genotype II includes isolates
from Brazil and Peru, and genotype III is represented by the
isolates from Brazil and Panama [18,19].
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venezuelensis in Trinidad [9]; Ochlerotatus serratus and Culex
quinquefasciatus in Brazil [20]) and frequently from the midge
Culicoides paraensis [9,21,22]. High population densities of this
midge have been found during epidemics of ORO virus [23].
Transmission of the virus has been demonstrated via C. paraensis,
from infected to susceptible hamsters, and from infected humans
to susceptible hamsters [20,24]. ORO virus has also been isolated
from sloths (Bradypus tridactylus [20]), and from a monkey (Callithrix
sp.) in Brazil [10].
In 1995, the U.S. Naval Medical Research Unit Six (NAMRU-
6) in Lima, in collaboration with the Ministry of Health of Peru,
initiated a passive surveillance study to investigate etiology of
febrile illnesses. As part of these surveillance activities, several
ORO-like strains were obtained from febrile patients in Iquitos,
Peru. In this study, we describe the identification of a novel
reassortant virus which we named Iquitos (IQT) based on the
location of the isolation of the virus. Specifically, we: 1)
demonstrated that IQT virus causes clinical disease in humans
similar to ORO fever, 2) described the genetic relationship of IQT
virus to other members of the Simbu serogroup, 3) identified the
risk factors associated with human infection by IQT virus in an
urban setting of the Amazon region of Peru, and 4) describe the
clinical manifestations associated with infection. Significantly,
immunity to ORO virus does not appear to protect against
infection by IQT virus, and both ORO and IQT viruses appear to
have similar antibody prevalence in Iquitos over the past 10 years.
Materials and Methods
Viruses
The IQT1690 ORO strain used in this study was isolated in
1995 from a 50 year-old male resident of Iquitos, Peru. The first
strain of IQT virus (IQT9924) was isolated in Iquitos from a 13
year-old boy (Table 1). The origin of the ORO strains
BeH379693, BeH544552, MD023, GML444477 and GML
445252 were previously described [18,19].
Study site
Iquitos is a city of about 380,000 inhabitants located 120 meters
above sea level in the Amazon Basin in northeastern Peru.
Febrile surveillance study population
The human use study protocols were approved by the Ministries
of Health of Peru and by the NAMRU-6 Institutional Review
Board (protocol NMRCD.2000.0006). The study subjects were
patients ($ 5 years of age) who presented with a diagnosis of an
acute, febrile undifferentiated illness at military or civilian
outpatient clinics in Iquitos. The criteria for inclusion in the
program was fever $ 38uC of no more than five days duration,
headache, myalgia and other nonspecific symptoms. Demographic
and clinical information were obtained from each patient at the
time of voluntary enrollment and a signed consent form was
obtained from patients 18 years of age and older. In addition,
written assent was obtained from patients between 8 and 17 years
of age. For patients younger than 18 years, written consent was
obtained from parents or legal guardians. Paired-blood samples
were collected, one during the acute phase of illness and a second
sample 2-4 weeks after onset of symptoms.
Virus isolation and serological assay
Acute serum samples were tested for virus by cell culture, and
both acute and convalescent serum samples were assayed for IgM
antibody to a variety of arboviruses by an enzyme-linked
immunosorbent assay (ELISA), as described previously [25].
For virus isolation attempts, serum samples were diluted 1:5 in
Eagle’s minimum essential medium (EMEM) supplemented with
2% fetal bovine serum, 200 mg of streptomycin, and 200U/ml of
penicillin. Two hundred ml of the diluted samples were inoculated
into flasks containing either confluent monolayers of African green
monkey kidney (Vero) cells or Aedes albopictus mosquito (C6/36)
cells. Vero and C6/36 cell cultures were maintained at 37uC and
28uC, respectively, and were examined daily for 10 days for
evidence of viral cytopathic effects (CPE). Spot-slides of C6/36
and Vero cells were subsequently prepared on days 10 post-
inoculation of the samples (or sooner if CPE developed) and an
immunofluorescence assay (IFA) was performed using polyclonal
antibody against arboviruses endemic to Peru, including ORO
virus [17,25,26,27,28,29,30].
Neutralizing antibody prevalence studies
A total of 1037 human serum samples collected in Iquitos
during 2006 were tested for IgG antibody to the ORO strain
IQT1690 and IQT9924 virus using a previously described ELISA
[25]. The samples were collected as part of a cross-sectional
antibody prevalence study conducted in Iquitos after an outbreak
of febrile illness associated with Venezuelan equine encephalitis
virus (VEEV) infection (protocol PJT.NMRCD.001). Three
neighborhoods where VEE cases were reported and a control
neighborhood where VEE cases were not reported were included
in the study [31]. Serum samples from a subset of the original
study participants who agreed to future use of their samples were
tested by ELISA IgG antibody. ELISA positive samples were
further tested using an 80% plaque reduction neutralization assay
(PRNT) each for the ORO strain IQT 1690 and IQT9924 virus.
Briefly, sera were heat-inactivated at 56uC for 30 minutes and 2-
fold serum dilutions were prepared and mixed with 100 plaque
forming units (PFUs) of each virus and incubated at 4uC overnight.
The virus-serum dilutions mixtures were inoculated into confluent
monolayer of Vero cells propagated in microplates and incubated
at 37uC for 1 hour before adding an overlay of 0.4% of agarose in
EMEM. After 72 hours of incubation at 37uC, the plates were
stained with 0.25% crystal violet in 20% methanol and plaques
were counted. All IgG antibody positive samples were tested at an
initial concentration of 1:20 and all positive samples were further
titrated to determine endpoint titers. Neutralization titers were
Author Summary
Oropouche (ORO) virus is one of the few human
pathogens in the Orthobunyavirus genus in the family
Bunyaviridae. Phylogenetic analyses of ORO-like strains
isolated from febrile patients in Iquitos, Peru, identified a
novel ORO reassortant virus, which we named Iquitos (IQT)
virus based on the location of the isolation of the virus.
This novel pathogen was first isolated during 1999 from a
13-year-old boy who had an illness that included
symptoms of fever, headache, eye pain, body pain,
arthralgias, diarrhea, and chills. Subsequently, the virus
was identified as the cause of outbreaks of ‘‘Oropouche
fever’’ during 2005 and 2006 in Iquitos. Limited serological
studies indicate that prior infection with ORO virus does
not seem to protect against disease caused with the IQT
virus infection. In summary, we identified a new Orthobu-
nyavirus human pathogen in the Amazon region of Peru;
these results highlight the need for strengthening
surveillance activities and investigating the emergence of
new pathogens in tropical regions of South America.
Iquitos Virus: A Novel Human Pathogen
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formation by $ 80%.
Extraction of RNA, RT and PCR amplification of S, M and L
segments
Viral RNA was extracted using the QIAamp viral RNA mini kit
(Qiagen, Valencia, CA) or Trizol reagent (Invitrogen, Carlsbad, CA)
following the manufacturer’s protocols. The reverse transcription
reaction (RT) was done using 1X RT buffer, 0.2 mM dNTPs, 1 mM
of primers, 80 units of RNAsin ribonuclease inhibitor (Promega,
Madison, WI), 1mM of dithiothreitol, 200U of SuperScript reverse
transcriptase (Invitrogen) and 5 mlo fR N A .T h er e a c t i o n sw e r e
incubated at 42uC for 1 hour. The PCR included 1X PCR buffer,
0.25 mM dNTPs, 1 mM of primers, 3 mM of MgCl2, 2.5 units of
GoTaq DNA polymerase (Promega, Madison, WI) and 5 mlo f
cDNA. The conditions for the PCRs included incubation at 94uCf o r
2m i n u t e s ,3 5c y c l e so f9 4 uC for 30 seconds, 50uC for 1 minute, 72uC
for 1.5 minutes and a final extension of 72uC for 10 minutes to ensure
complete double-stranded DNA synthesis. The primers used for the
PCR amplification have been previously described and included
ORO N3 (GTGAATTCCCACTATATGCCAATTCCGAATT)
and ORO N5 (AAAGAGGATCCAATAATGTCAGAGTT-
CATTT) that amplifies the S segment, M14C (CGG AAT TCA
GTA GTG TAC TACC) and M619R (GAC ATA TG (CT) TGA
TTG AAG CAA GCA TG) that amplifies the M segment and
M13CBunL1C (TGTAAAACGACGGCCAGTAGTGTACTC-
CT), and BunL605R (AGTGAAGTCICCATGTGC) that amplifies
the L segment [3,10,19].
Sequencing and phylogenetic analyses
Partial sequences of the S, M, and L segments were obtained
and compared to published ORO virus sequences. Purified PCR
products were sequenced directly and sequencing analyses of the
PCR products were performed using an Applied Biosystems Prism
automated DNA sequencing kit (Foster City, CA) according to the
manufacturer’s’ protocols. Sequences were aligned using the
Clustal program in the Mac Vector software package (MacVector
Inc., Cary, NC) and phylogenetic analyses were performed using
the maximum parsimony, neighbor joining, and maximum
likelihood methods implemented in the PAUP software [32,33].
For the neighbor joining analyses, the HKY85 distance was used.
Bootstrap values, to place confidence values on grouping within
trees, were calculated based on 500–1000 replicates.
Serological reagents and antigenic characterization of
ORO-like viruses
To prepare ORO virus hyperimmune ascitic fluid for classical
cross-neutralization tests, mice received 4 weekly intraperitoneal
(IP) injections of virus-infected newborn mouse brain suspension
with Freud’s adjuvant. To investigate antigenic differences among
the viruses, cross-neutralization assays were then performed, using
a previously described PRNT [34]. To further evaluate the
antigenic differences between the ORO strain IQT1690 and
IQT9924 virus, acute and convalescent sera from patients infected
with these viruses were tested against both strains using PRNT.
Hamster lethal dose 50 (LD50) studies
Three to 4 week-old golden Syrian female hamsters were
inoculated (IP) with serial 10-fold dilutions of virus. The LD50 was
calculated by the Reed and Muench method [35].
Viremia levels
To determine viremia levels in infected patients, serum samples
were prepared in 10-fold dilutions and 100 ml of each dilution was
inoculated onto confluent monolayers of Vero cells in 12 well-
plates. Viruses were adsorbed to the monolayers for 1 hour at
37uC. A 3-ml overlay consisting of EMEM with 0.4% agarose was
Table 1. Viremia titer for human febrile cases in Iquitos, Peru, included in the study.
CODE COLLECTION DATE ONSET AGE GENDER Viremia (PFU/ml) Virus
IQT1690 6 Apr-95 1 Apr-95 50 Male 7610
5 ORO
IQT7085 6 Apr-98 5 Apr-98 28 Male 6610
3 ORO
IQT9924 12 Feb-99 10 Feb-99 13 Male ,100 IQT
IQD5900 25 Jun-03 22 Jun-03 34 Female 1.2610
4 IQT
IQE1005 30 Mar-05 29 Mar-05 30 Male ,100 IQT
IQE1217 25 Apr-05 19 Apr-05 24 Male 1.8610
5 IQT
IQE1283 3 May-05 1 May-05 30 Female 4.4610
3 IQT
IQE1704 6 Jul-05 5 Jul-05 27 Female ,100 IQT
IQE1816 19 Jul-05 17 Jul-05 15 Female 1.2610
4 IQT
IQE1819 21 Jul-05 17 Jul-05 40 Male 1.8610
4 IQT
IQE2257 2 Nov-05 1 Nov-05 22 Male 7.6610
4 IQT
IQE2718 19 Jan-06 18 Jan-06 21 Male 4.2610
4 IQT
IQE2791 27 Jan-06 24 Jan-06 32 Female 6610
2 IQT
IQE2803 30 Jan-06 29 Jan-06 28 Male 2610
2 IQT
IQE2973 13 Feb-06 12 Feb-06 15 Male 1.8610
4 IQT
IQE3173 27 Feb-06 26 Feb-06 55 Female 2.2610
4 IQT
IQE3248 3 Mar-06 1 Mar-06 21 Female 6610
4 IQT
IQE3728 21 Apr-06 20 Apr-06 25 Male ,100 IQT
NFI0309 23 Feb-06 21 Feb-06 35 Male 3610
4 IQT
doi:10.1371/journal.pntd.0001315.t001
Iquitos Virus: A Novel Human Pathogen
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plugs were removed, and the cells were stained with 0.25% crystal
violet in 20% methanol. The sensitivity of the assay corresponded
to a detection limit of 100 PFU/ml.
Statistical analyses
The analysis was performed using SPSS 17.0 for Windows
(SPSS Inc, Chicago, IL, USA). The proportions of positive results
(PRNT for IQT1690 and IQT9924 antibody $ 20) were
calculated with their respective 95% confidence intervals (95%
CI). The proportions were compared using the Pearson Chi-
Square and Fisher exact tests. A 2-tailed p-values , 0.05 was used
for all statistical analyses. Multivariate analysis was performed
using logistic regression (enter method) adjusting by gender, age
(adult, child), occupation, type of house, contact with domestic
animals, travel history and neighborhoods.
Results
Identification of IQT9924 virus as a novel reassortant
Orthobunyavirus
In 1999, IQT virus strain IQT9924 was isolated in Iquitos,
Peru, from a 13-year-old boy who had an illness that included
symptoms of fever, headache, eye pain, body pain, arthralgias,
diarrhea, and chills. These clinical symptoms were typical of ORO
virus infections in Peru [17]. The strain was provisionally
identified as ORO virus based on results of serological reactivity
in an indirect immunofluorescence test with virus-infected cells.
Sixteen additional IQT9924 virus isolates (provisionally identified as
ORO virus) were obtained from febrile patients living in Iquitos: 1 in
2003, 7 in 2005, and 8 in 2006. Of the 17 IQT 9924 virus positive
patients, detailed clinical information was available for 16 (Table 2).
The most common general symptoms were: chills (16), headache (15),
arthralgia or loss of joint function (15), general malaise (14), diminished
appetite (13), myalgias (13), retro-orbital pain (11), bone pain (9), and
pallor (7). Gastrointestinal symptoms were very common, and 12
patients had at least one of the following symptoms: nausea (10),
abdominal pain (7), vomiting (4), or diarrhea (2). No patients had
jaundice, hepatomegaly, splenomegaly, abdominal distension, or
ascites. Six patients had at least one respiratory symptom: cough (6),
rhinorrhea (3), pharyngeal congestion (2), or expectoration (1); no
patient had dyspnea. Only one patient complained of a rash, and this
was described as erythematous and affecting both the central trunk and
distal extremities. With the exception of one patient who had
petechiae, none of the patients had hemorrhagic manifestations,
including epistaxis, bleeding gums, melena, hematochezia, vaginal
bleeding, petechiae, purpura, and ecchymosis. All patients had a fever
as this was one of the inclusion criteria.
Based on virus isolation and serological analyses, the peak
incidence for ORO virus was reported in Iquitos as occurring in
2004, 2005 and 2006 [30]. Because the circulation of IQT9924
virus only was detected serologically and genetically (see below)
during that time period, we believe that the study most likely
reported the incidence of IQT9924 virus.
Genetic analyses of the S, M, and L segments were conducted to
determine the relationships of the isolates to ORO virus and other
members of the Simbu serogroup. Phylogenetic trees were
constructed for both the S- and M-RNA segments based on
members of the Simbu serogroup that included an example from
each of the three known ORO genotypes [19]. The phylogenetic
tree based on the S segment placed the S-RNA of IQT9924 virus
among isolates of ORO virusgenotype II (Fig. 1),while the M-RNA
phylogenetic tree (Fig. 2) indicated that the strain IQT9924 had an
M-RNA that was unique from any other Simbu serogroup virus
identified to date, but was most closely related to ORO virus.
Significantly, IQT9924 virus had an M-RNA distinct from JAT
virus, a reassortant with a non-ORO virus M-RNA [6]. The L-
RNA phylogenetic tree showed that IQT9924 virus had an L-RNA
of ORO virus (data not shown). The M segment fragment sequence
(,590 nucleotides) of IQT9924 displayed only 68% nucleotide and
65%amino acid identity to the prototypeORO strains BeAn 19991
(Brazil) and Tr9760 (Trinidad) whereas the S and L segment
fragment sequences exhibited 95% nucleotide and 96% amino acid
identitytoOROvirus. BasedonpartialsequencesoftheS, MandL
segments, all ORO-like viruses isolated from patients living in
Iquitos after 1999 had similar genetic characteristics and would
appear to be examples of IQT9924 virus. Genetic analyses of ORO
virus isolates obtained in Peru before 1999, did not reveal the
circulation of IQT9924 virus prior to 1999 [19].
Antigenic characterization of IQT9924
We investigated the serological relationships of IQT9924 virus
using cross-neutralization tests. Mouse antisera were prepared
Table 2. Clinical signs and symptoms among patients (n=16)
infected with IQT 9924 virus.
Symptom Number Percentage
General
Chills 16 100%
Headache 15 94%
Arthralgia or Q joint function 15 94%
General malaise 14 88%
Diminished appetite 13 81%
Myalgias 13 81%
Retro-orbital pain 11 69%
Bone pain 9 56%
Pallor 7 44%
Gastrointestinal manifestations 12 75%
Nausea 10 63%
Abdominal pain 7 44%
Vomiting 4 25%
Diarrhea 2 13%
Jaundice 0 0%
Hepatomegaly 0 0%
Splenomegaly 0 0%
Abdominal distension 0 0%
Ascites 0 0%
Respiratory manifestations 6 38%
Cough 6 38%
Rhinorrhea 3 19%
Pharyngeal congestion 2 13%
Expectoration 1 6%
Cutaneous manifestations{ 16 %
Hemorrhagic manifestations{ 16 %
{The following items were evaluated for this category: Maculopapular rash,
erythematous rash, vesicles, and subcutaneous nodules.
{The following items were evaluated for this category: epistaxis, bleeding gums,
melena, hematochezia, vaginal bleeding, petechiae, purpura, and ecchymosis.
doi:10.1371/journal.pntd.0001315.t002
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virus. These antisera displayed a 4-fold or greater difference in
neutralization titer among these viruses (Table 3), indicating that
IQT9924 virus is serologically distinct from ORO and JAT viruses.
Next, convalescent sera from patients in Iquitos who had been
infected with either OROV or IQT9924 virus were assayed by
PRNT to confirm the antigenic differences. A 4-fold or greater
difference in neutralization titer was observed between these
viruses (Table 4) corroborating our initial findings with mouse
antisera. Of particular importance, neutralizing antibody to ORO
virus were detected in the acute serum samples of 2 febrile patients
from whom the IQT9924 virus had been isolated (Table 5).
Furthermore, a boost in ORO neutralizing antibody titers was
observed in both patients after infection with IQT9924 (Table 5).
Overall, the results suggest that prior ORO virus infection does
not protect against febrile disease caused by the new reassortant
virus (IQT 9924) and is consistent with the cross-neutralization
data indicating that IQT9924 and ORO are distinct viruses, and
Figure 1. Neighbor joining phylogenetic tree of the Oropouche virus based on the S segment. The tree was derived from recently
generated partial nucleoprotein gene sequences of recent ORO-like virus isolates from Peru (depicted in red or italics) and previously published
homologous sequences, using the neighbor joining program. Virus strains are labeled by code designation. The tree was rooted using an outgroup
comprised of Sathuperi virus. Numbers indicate bootstrap values for the clades to the right.
doi:10.1371/journal.pntd.0001315.g001
Iquitos Virus: A Novel Human Pathogen
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individuals can be infected and have clinical diseases caused by
both viruses.
Hamster virulence of IQT9924
The hamster is used as an animal model of ORO virus infection
[36]. Thus, we evaluated the hamster virulence phenotype of
IQT9924 virus and compared the results to those obtained with
representatives of the three ORO genotypes. The IQT 9924 virus was
found to be poorly virulent with a LD50 of 4220 PFU and was similar
to two Panamanian strains (GML 444477 and GML445252)
belonging to ORO genotype III that were non-lethal at the highest
doses inoculated (.2,500 and .2,000 PFU, respectively) (Table 6). In
comparison, ORO genotype II strain MD023 from Madre de Dios,
Peru, was virulent with LD50 of 45 PFU. Finally, two genotype I
strains, BeH379693 and BeH544552 from Brazil, displayed different
virulence phenotypes (.7,000 PFU vs 1 PFU, respectively).
Viremia levels
Since Simbu serogroup viruses are arboviruses, we undertook
preliminary studies with a limited number of serum samples to
determine viremia titers among ORO and IQT9924 virus-infected
patients. Serum infectivity titers were obtained from a total of 19
patients. Two ORO virus-infected patients had viremias of 6610
3
and 7610
5 PFU/ml whereas 17 patients infected with IQT9924
virus had levels that were below the limit of detection of the assay
(,100) to 1.8610
5 PFU/ml (Table 1).
Risk factors for ORO and IQT9924 virus infection in the
city of Iquitos, Peru
Examination of 1037 human serum samples from acute febrile
infections in Iquitos revealed that the overall neutralizing antibody
Figure 2. Neighbor-joining phylogenetic tree of the M segment RNA of members of the Simbu serogroup. The tree was constructed
based on partial sequences of the Gc gene. Bootstrap values were obtained based on 500 replicates. Virus abbreviations are as follows: Kai, Kaikalur;
Shu, Shuni; Dou, Douglas; Sat, Sathuperi; Sim, Simbu; San, Sango; Sha, Shamonda; But, Buttonwillow; Uti, Utinga; Ing, Ingwavuma; Mer, Mermet; Man,
Manzanilla; FP, Facey’s Paddock; Thi, Thimiri; Jat, Jatobal; ORO, Oropouche.
doi:10.1371/journal.pntd.0001315.g002
Table 3. Neutralization of ORO, IQT9924 and JAT virus by
mouse antisera.
Mouse Immune Ascitic Fluid
Virus Anti-Trinidad 55 Anti-IQT9924 Anti-JAT
Trinidad 55
(ORO)
.20,480 40 ,20
IQT 9924 ,20 .20,480 ,20
JAT ,20 ,20 1280
Neutralization titers are expressed as the dilution of mouse immune ascitic fluid
antiserum inhibiting 80% of plaque forming units.
doi:10.1371/journal.pntd.0001315.t003
Iquitos Virus: A Novel Human Pathogen
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17.1) whereas prevalence to IQT9924 virus was 15.4% (160/1037)
(95% CI 13.3–17.7). Only 3.4% (35/1037) of the serum samples
had neutralizing antibodies (.20) to both viruses. Neutralizing
antibody prevalence to both ORO and IQT9924 viruses was
higher among females than males (17.3% vs 10.2% and 17.5% vs
11.3%, respectively; p,0.05).
The neutralizing antibody prevalence to ORO virus in persons
living in the neighborhoods of San Juan (24.1%) and Bellavista
Nanay (16.5%) was higher compared to other neighborhoods
(Fig. 3). Similarly, the PRNT antibody prevalence to IQT9924
virus was also higher in the neighborhoods of San Juan (33.9%)
and Bellavista Nanay (12.2%). In San Juan, PRNT antibody
prevalence to IQT9924 virus was significantly higher than to
ORO virus (p,0.05). Neutralizing antibody prevalence to both
viruses in the study population increased with age after adulthood
(0% in 5–9 years old to 32.3% in 40-49 years old for ORO virus
and 3.6% in 5–9 years old to 25% in .70 years old for IQT9924
virus) (Table 7). The antibody prevalence to ORO and IQT9924
viruses in adults was 20.1% and 18.8%, respectively, compared to
2.8% and 7.9% in the younger group (,20 years old). The
univariate analysis did not detect an association between ORO or
IQT9924 virus antibody prevalence and occupation, type of
housing, travel or contact with chickens or rodents.
Logistic regression models were used to test the significance of
each factor. The variables predictive of ORO virus neutralizing
antibody prevalence in the model were gender, age and
neighborhood, whereas factors such as gender, age, neighborhood,
and contact with pigs were predictive of IQT9924 virus antibody
prevalence.
Discussion
The first confirmed ORO fever cases in Peru were reported in
1992 involving a small outbreak of eight febrile cases living in
Iquitos [37]. Subsequently, only sporadic cases of ORO fever were
reported in Peru, mainly in the Amazon region. The situation in
Peru differs from Brazil, where ORO fever outbreaks are usually
associated with hundreds of human cases [11,18,38]. The reasons
for this apparent difference in ORO transmission rates remain
unknown. To date, three ORO genotypes have been described
based on the nucleoprotein gene (S segment): genotype I among
viruses circulating in Brazil and Trinidad, genotype II among
viruses from Brazil and Peru, and genotype III among viruses from
Brazil and Panama [10,18,19]. In this study, we sought to
genetically characterize strains from Peru that were provisionally
identified as ORO virus. Sequence analyses based on the S and L
segments placed the strain IQT9924, isolated in Iquitos in 1999,
within ORO genotype II while phylogenetic analyses of the M
segment revealed that IQT9924 virus contained a M-RNA
segment of a still unidentified Simbu-serogroup virus. Thus,
IQT9924 was identified as a Simbu serogroup reassortant virus.
Serological characterization of IQT9924 virus confirmed that the
virus was distinct from ORO virus. More importantly, we
obtained serological evidence that prior ORO virus infection
does not protect against clinical disease caused by this new
reassortant virus, providing additional confirmation that ORO
and IQT9924 are two distinct viral entities. Because most
arbovirus laboratories in South America identify ORO virus
without detailed serological or genetic characterization, it is
uncertain whether IQT9924 circulates in other South American
countries. Further genetic and antigenic characterization of ORO
isolates from South America is necessary to fully determine the
geographic distribution of this newly identified human pathogen.
Studies conducted in Brazil reported viremia titers higher than
3log10 suckling mice LD50 (SMLD50)/ml among ORO- infected
patients, including approximately 10% of the patients who developed
Table 4. Antigenic characterization of ORO and IQT9924 (IQT)
viruses.
Convalescent sera Virus strain
IQT 1690 (ORO) IQT 9924 (IQT)
IQT 4191 (ORO) 40 ,40
FSE 813 (ORO) $640 ,20
IQU 224 (IQT) ,40 $320
IQE 1922 (IQT) ,20 80
IQE 1936 (IQT) ,20 160
IQE 2391 (IQT) ,20 80
IQE 3811 (IQT) ,20 40
IQE 3409 (IQT) ,20 80
IQE 3473 (IQT) ,20 80
The PRNT assay was done using convalescent sera from febrile patients infected
with ORO or IQT9924 (IQT) virus. The PRNT titers are presented as the reciprocal
of the highest serum dilution capable of neutralizing 80% of approximately 100
plaque-forming units (PFU) of virus.
doi:10.1371/journal.pntd.0001315.t004
Table 5. Past infection with ORO virus does not protect
against disease with IQT9924 (IQT) virus.
Case Virus strain
IQT 1690 (ORO) IQT 9924 (IQT)
Patient 1
IQE 1005 acute
320 ,20
IQE 1106 convalescent $640 $640
Patient 2
IQE 2803 acute
160 ,20
IQE3122 convalescent $640 320
Two febrile patients had ORO neutralizing antibodies in the acute sera where
IQT virus was isolated. The PRNT titers are presented as the reciprocal of the
highest serum dilution capable of neutralizing 80% of approximately 100
plaque-forming units (PFU) of virus.
doi:10.1371/journal.pntd.0001315.t005
Table 6. Hamster virulence of ORO and IQT9924 viruses.
Virus
ORO
genotype
Lethality
(PFU/LD50)
Average survival
time (days)
BeH379693 I .7,000 NA
BeH544552 I 1 5.0*
MD023 II 45 6.5**
GML444477 III .2,500 NA
GML445252 III .2,000 NA
IQT9924 NA 4220 5.5
*at a virus inoculum of 2,000 PFU.
**at a virus inoculum of 14,000 PFU.
NA: Not applicable.
doi:10.1371/journal.pntd.0001315.t006
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first two days of illness [20]. These levels of viremia were high enough
to infect C. paraensisand transmission was demonstrated to susceptible
hosts. Consequently, it has been postulated that humans are the
primary amplifying host during ORO fever epidemics [20,24]. In
contrast, viremia levels lower than 5.3log10 SMLD50/ml were not
sufficient to infect C. paraensis [24]. In this study, we measured viremia
by plaque assay (instead of SMLD50) and found that the average
viremia levels detected among ORO and IQT9924 virus-infected
patients were 4.860.7 log10 PFU/ml and 3.461.1 log10 PFU/ml,
respectively with at least one ORO-infected patient developing a
viremia titer of 5.9 log10 PFU/ml (Table 1).
It is not known if C. paraensis is the vector of IQT9924 virus.
However, studies conducted in and around Iquitos during 1996–
1997 identified C. paraensis as the most common biting midge of all
host-seeking ceratopogonids at 16 sites and C. insinuatus being the
second most common biting midge [39,40]. Subsequent studies
conducted in 2001, 2002, and 2003 showed that the peaks in
biting activities in the Punchana district, located near Iquitos,
occurred between October and December for C. paraensis.
Likewise, peaks in biting activities were observed between October
and April for C. insinuatus in Santa Clara, near Iquitos [40]. It has
not been possible to determine peak incidence rates of ORO fever
due to lack of identification of cases. In contrast, data from our
Figure 3. ORO and IQT9924 antibody prevalence among residents from different neighborhoods in Iquitos. ORO virus antibody
prevalence is shown in black, underlined numbers represent IQT9924 virus antibody prevalence.
doi:10.1371/journal.pntd.0001315.g003
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virus-infected patients peak from December to April indicating a
possible overlap with the biting activities of C. insinuatus [30].
Felippe-Bauer et al [41] recently identified two new morphological
species in the C. paraensis complex from the Department of
Amazonas and Loreto, Peru. Thus, future studies should
investigate the role of this midge in ORO and IQT9924 virus
transmission.
In Iquitos, the overall neutralizing antibody prevalence for
ORO virus was 14.9% whereas prevalence for IQT9924 virus was
15.4%. These numbers are lower than those from previous studies
that reported antibody prevalence to ORO virus (based mostly on
IgG antibodies) as high as 35% in certain neighborhoods near
Iquitos [14,15]. Thus, it would appear that ORO virus prevalence
varies among neighborhoods and this was demonstrated in our
study where neighborhoods, such as San Juan and Bellavista
Nanay, have higher ORO virus prevalence rates. Antibody
prevalence to ORO and IQT9924 viruses was higher among
females and is consistent with previous studies on ORO virus
prevalence [15,42]. Another study carried out in Brazil after an
ORO virus outbreak also detected higher antibody prevalence
among women [43]; however, a subsequent study in Brazil failed
to detect gender differences in attack rates [20].
Our clinical data indicate that the IQT9924 virus shares many
of the same clinical manifestations as ORO virus. Headache and
chills affected the vast majority of IQT9924-infected patients,
similar to previous studies of ORO virus infection [18,42]. Bone,
muscle, and joint pain also were observed commonly for both
viruses. Rash and hemorrhagic manifestations have not been
classically described with ORO virus infection and were only
found in one of 16 IQT9924-infected patients in this study.
Interestingly, respiratory complaints—primarily cough—were
found in 38% of our IQT9924-infected patients, a finding not
commonly reported with ORO virus infection.
Among the Orthobunyavirus genus, studies have shown that the
pathogenicity of these viruses is multigenic with the M segment
being a major determinant [44]. Thus, it is very likely that the
donor of IQT9924 virus M segment may also cause human illness
in the Amazon region of Peru. It is worth noting that this new virus
was first isolated in 1999 and, subsequently in 2005 and 2006,
when it was the cause of outbreaks of febrile illness in Iquitos.
Some of the patients infected with the IQT9924 virus in 2005 and
2006 resided within Quistococha and Zungarococha, which are
considered rural areas near Iquitos. Thus, it is possible that a spill-
over of cases occurred from rural to urban areas as was suggested
during the 2005-2006 VEEV outbreaks in Iquitos [31]. Unusual
high annual river levels occurred in early 2006, which may had an
impact on arthropod density and geographic distribution leading
to the observed VEEV and IQT9924 virus outbreaks. Finally, it
appears that this IQT9924 virus has emerged and possibly
replaced ORO virus in Iquitos because ORO virus cases have not
been identified in the area since 1999.
In summary, this study identified a new pathogen, IQT9924 a
reassortant of ORO virus that was associated with febrile illness in
the Amazon region of Peru. We propose the name Iquitos virus for
this newly identified Orthobunyavirus member of the Simbu-
serogroup because there have been cases of disease caused by
this virus in the Iquitos area over several years. While reassortment
among members of the same serogroup of the Bunyaviridae has been
identified, few reassortants have been associated with human
disease. It will be important to determine the geographic
distribution of Iquitos virus and to evaluate its potential as a
major public health problem as ORO virus has been done in
Brazil.
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